{"title":"上市前药品不良反应:数据管理程序。在临床试验早期意外死亡。","authors":"A Cato","doi":"10.1177/009286158702100103","DOIUrl":null,"url":null,"abstract":"<p><p>Reporting of adverse events occurring during clinical trials of investigational drugs is a complex and controversial issue. Even the interpretation of the term, \"adverse event,\" cannot be agreed upon by researchers. The ultimate adverse event, death, presents even a greater challenge. This paper presents an actual case of death during a clinical trial to illustrate a methodological approach to deal with such an event.</p>","PeriodicalId":51023,"journal":{"name":"Drug Information Journal","volume":"21 1","pages":"3-7"},"PeriodicalIF":0.0000,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/009286158702100103","citationCount":"3","resultStr":"{\"title\":\"Premarketing adverse drug experiences: data management procedures. Unexpected death occurring early in clinical trials.\",\"authors\":\"A Cato\",\"doi\":\"10.1177/009286158702100103\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Reporting of adverse events occurring during clinical trials of investigational drugs is a complex and controversial issue. Even the interpretation of the term, \\\"adverse event,\\\" cannot be agreed upon by researchers. The ultimate adverse event, death, presents even a greater challenge. This paper presents an actual case of death during a clinical trial to illustrate a methodological approach to deal with such an event.</p>\",\"PeriodicalId\":51023,\"journal\":{\"name\":\"Drug Information Journal\",\"volume\":\"21 1\",\"pages\":\"3-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/009286158702100103\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Information Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/009286158702100103\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Information Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/009286158702100103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Premarketing adverse drug experiences: data management procedures. Unexpected death occurring early in clinical trials.
Reporting of adverse events occurring during clinical trials of investigational drugs is a complex and controversial issue. Even the interpretation of the term, "adverse event," cannot be agreed upon by researchers. The ultimate adverse event, death, presents even a greater challenge. This paper presents an actual case of death during a clinical trial to illustrate a methodological approach to deal with such an event.